Overview

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2030-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy versus placebo combined with concurrent chemoradiotherapy in patients with locally advanced cervical squamous cell carcinoma. The primary hypotheses are that nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival.

Phase:

PHASE3

Details

Lead Sponsor:

Biotech Pharmaceutical Co., Ltd.

Treatments:

Brachytherapy
Cisplatin
nimotuzumab